148 related articles for article (PubMed ID: 21328314)
1. Predicting diafiltration solution compositions for final ultrafiltration/diafiltration steps of monoclonal antibodies.
Teeters M; Bezila D; Benner T; Alfonso P; Alred P
Biotechnol Bioeng; 2011 Jun; 108(6):1338-46. PubMed ID: 21328314
[TBL] [Abstract][Full Text] [Related]
2. Theoretical analysis of excipient concentrations during the final ultrafiltration/diafiltration step of therapeutic antibody.
Miao F; Velayudhan A; DiBella E; Shervin J; Felo M; Teeters M; Alred P
Biotechnol Prog; 2009; 25(4):964-72. PubMed ID: 19569193
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic model of pH and excipient concentration during ultrafiltration and diafiltration processes of therapeutic antibodies.
Ladwig JE; Zhu X; Rolandi P; Hart R; Robinson J; Rydholm A
Biotechnol Prog; 2020 Sep; 36(5):e2993. PubMed ID: 32185869
[TBL] [Abstract][Full Text] [Related]
4. A Small-Scale Process for Predicting Donnan and Volume Exclusion Effects During Ultrafiltration/Diafiltration Process Development.
Abel J; Kosky A; Ball N; Bacon H; Kaushik R; Kleemann GR
J Pharm Sci; 2018 May; 107(5):1296-1303. PubMed ID: 29339134
[TBL] [Abstract][Full Text] [Related]
5. A mechanistic model to account for the Donnan and volume exclusion effects in ultrafiltration/diafiltration process of protein formulations.
Yu Z; Moomaw JF; Thyagarajapuram NR; Geng SB; Bent CJ; Tang Y
Biotechnol Prog; 2021 Mar; 37(2):e3106. PubMed ID: 33289341
[TBL] [Abstract][Full Text] [Related]
6. Effect of protein and solution properties on the Donnan effect during the ultrafiltration of proteins.
Bolton GR; Boesch AW; Basha J; Lacasse DP; Kelley BD; Acharya H
Biotechnol Prog; 2011; 27(1):140-52. PubMed ID: 21312362
[TBL] [Abstract][Full Text] [Related]
7. Predicting Formulation Conditions During Ultrafiltration and Dilution to Drug Substance Using a Donnan Model with Homology-Model Based Protein Charge.
Kannan A; Chinn M; Izadi S; Maier A; Dvornicky J; Fedesco M; Day E; Ladiwala A; Woys A
J Pharm Sci; 2023 Mar; 112(3):820-829. PubMed ID: 36336103
[TBL] [Abstract][Full Text] [Related]
8. Designing scalable ultrafiltration/diafiltration process of monoclonal antibodies via mathematical modeling by coupling mass balances and Poisson-Boltzmann equation.
Ambrožič R; Arzenšek D; Podgornik A
Biotechnol Bioeng; 2021 Feb; 118(2):633-646. PubMed ID: 33049074
[TBL] [Abstract][Full Text] [Related]
9. Mass Balance Model with Donnan Equilibrium Accurately Describes Unusual pH and Excipient Profiles during Diafiltration of Monoclonal Antibodies.
Baek Y; Singh N; Arunkumar A; Borwankar A; Zydney AL
Biotechnol J; 2019 Jul; 14(7):e1800517. PubMed ID: 30791230
[TBL] [Abstract][Full Text] [Related]
10. pH and excipient profiles during formulation of highly concentrated biotherapeutics using bufferless media.
Jabra MG; Tao Y; Moomaw JF; Yu Z; Hotovec BJ; Geng SB; Zydney AL
Biotechnol Bioeng; 2020 Nov; 117(11):3390-3399. PubMed ID: 32667708
[TBL] [Abstract][Full Text] [Related]
11. Small molecule clearance in ultrafiltration/diafiltration in relation to protein interactions:Study of citrate binding to a Fab.
Harinarayan C; Skidmore K; Kao Y; Zydney AL; van Reis R
Biotechnol Bioeng; 2009 Apr; 102(6):1718-22. PubMed ID: 19132743
[TBL] [Abstract][Full Text] [Related]
12. Protein-solute interactions affect the outcome of ultrafiltration/diafiltration operations.
Stoner MR; Fischer N; Nixon L; Buckel S; Benke M; Austin F; Randolph TW; Kendrick BS
J Pharm Sci; 2004 Sep; 93(9):2332-42. PubMed ID: 15295793
[TBL] [Abstract][Full Text] [Related]
13. Near Infrared Spectroscopy as a PAT tool for monitoring and control of protein and excipient concentration in ultrafiltration of highly concentrated antibody formulations.
Thakur G; Hebbi V; Rathore AS
Int J Pharm; 2021 May; 600():120456. PubMed ID: 33711473
[TBL] [Abstract][Full Text] [Related]
14. pH variations during diafiltration due to buffer nonidealities.
Baek Y; Yang D; Singh N; Arunkumar A; Ghose S; Li ZJ; Zydney AL
Biotechnol Prog; 2017 Nov; 33(6):1555-1560. PubMed ID: 28840650
[TBL] [Abstract][Full Text] [Related]
15. Optimization of ultrafiltration/diafiltration processes for partially bound impurities.
Shao J; Zydney AL
Biotechnol Bioeng; 2004 Aug; 87(3):286-92. PubMed ID: 15281103
[TBL] [Abstract][Full Text] [Related]
16. An alternate diafiltration strategy to mitigate protein precipitation for low solubility proteins.
Gefroh E; Lutz H
Biotechnol Prog; 2014; 30(3):646-55. PubMed ID: 24449613
[TBL] [Abstract][Full Text] [Related]
17. Quality by design: impact of formulation variables and their interactions on quality attributes of a lyophilized monoclonal antibody.
Awotwe-Otoo D; Agarabi C; Wu GK; Casey E; Read E; Lute S; Brorson KA; Khan MA; Shah RB
Int J Pharm; 2012 Nov; 438(1-2):167-75. PubMed ID: 22944306
[TBL] [Abstract][Full Text] [Related]
18. High performance liquid chromatography (HPLC) based direct and simultaneous estimation of excipients in biopharmaceutical products.
Hebbi V; Chattopadhyay S; Rathore AS
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jun; 1117():118-126. PubMed ID: 31005704
[TBL] [Abstract][Full Text] [Related]
19. Streamlining process characterization efforts using the high throughput ambr® crossflow system for ultrafiltration and diafiltration processing of monoclonal antibodies.
Fernandez-Cerezo L; Benner SW; Pollard JM
Biotechnol Prog; 2021 May; 37(3):e3118. PubMed ID: 33369289
[TBL] [Abstract][Full Text] [Related]
20. Separation of monoclonal antibody alemtuzumab monomer and dimers using ultrafiltration.
Wan Y; Vasan S; Ghosh R; Hale G; Cui Z
Biotechnol Bioeng; 2005 May; 90(4):422-32. PubMed ID: 15812802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
